Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
Authors:
- Tabea TracksdorfTTTabea Tracksdorf
- D. Max SmithDSD. Max Smith
- Skyler PearseSPSkyler Pearse
- Emily J. CicaliECEmily J. Cicali
- Christina L. AquilanteCAChristina L. Aquilante
- Stuart A. ScottStuart A. Scott
- Teresa T. HoTHTeresa T. Ho
- Jai N. PatelJPJai N. Patel
- J. Kevin HicksJ. Kevin Hicks
- Daniel L. HertzDHDaniel L. Hertz
- 9 July 2024
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (8) , 1-10
Abstract
Purpose Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries, but not the United States (US). This survey assessed pre-treatment DPYD testing approaches in the US to identify best practices for broader adoption. Methods From August to October 2023, a 22-item QualtricsXM survey was sent to institutions and clinicians known to conduct pre-treatment DPYD testing and broadly distributed through relevant organizations and social networks. Responses were analyzed using descriptive analysis. Results Responses from 24 unique US sites that have implemented pre-treatment DPYD testing or have a detailed implementation plan in place were analyzed. Only 33% of sites ordered DPYD testing for all FP-treated patients; at the remaining sites, patients were tested depending on disease characteristics or clinician preference. Almost 50% of sites depend on individual clinicians to remember to order testing without the assistance of electronic alerts or workflow reminders. DPYD testing was most often conducted by commercial laboratories that tested for at least the four or five DPYD variants considered clinically actionable. Approximately 90% of sites reported receiving results within 10 days of ordering. Conclusion Implementing DPYD testing into routine clinical practice is feasible and requires a coordinated effort among the healthcare team. These results will be used to develop best practices for the clinical adoption of DPYD testing to prevent severe and fatal toxicity in cancer patients receiving FP chemotherapy.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine ChemotherapyClinical Pharmacology & Therapeutics, 2023
- Implementation of dihydropyrimidine dehydrogenase deficiency testing in EuropeESMO Open, 2023
- A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyThe Lancet, 2023
- Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon CancerClinical Colorectal Cancer, 2022
- Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyClinical Pharmacology & Therapeutics, 2022
- PathogenicDPYDVariants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical ImplementationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet TherapyClinical Pharmacology & Therapeutics, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime timeEuropean Journal of Cancer, 2016